

CERTIFICATE

Survey of 30 May 2025

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Molecular Genetics 33 - Fragile X Syndrome (FMR1 Gene, CGG Repeats) (781):

Validity 24 months:

FMR1 gene CGG-repeats analysis (R:B5)

FMR1 gene variant category

interpretation of results

(R) analysis is subject to the RiliBÄK

Customer:
10041629
Medyczne Laboratoria Diagnostyczne
INVICTA Sp. z o.o.
Polna 64
81-740 Sopot

Düsseldorf, 25 June 2025



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. rer. nat. Morten O. Christensen
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 30 May 2025

You have participated in the External Quality Assessment with the following analysis

Molecular Genetics 33 - Fragile X Syndrome (FMR1 Gene, CGG Repeats) (781):

FMR1 gene CGG-repeats analysis (R:B5)

FMR1 gene variant category

interpretation of results

(R) analysis is subject to the RiliBÄK

Customer:
10041629
Medyczne Laboratoria Diagnostyczne
INVICTA Sp. z o.o.
Polna 64
81-740 Sopot

Düsseldorf, 25 June 2025



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. rer. nat. Morten O. Christensen
(Adviser)